European Primary Care Cardiovascular Society
This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.
Large-scale observational data from the SWEDEHEART registry showed that in patients in clinical practice early and aggressive LDL-c lowering after MI was associated with reduced risk of major CV outcomes and mortality.
In a contemporary primary prevention cohort, MI and ASCVD event rates increased with higher LDL-c and older age.
Although relative risk for MI per 1 mmol/L higher LDL-c is similar across age groups, absolute risk for MI and ASCVD per LDL categories is much higher in individuals 80-100 years compared to those <70 years.
An observational study showed that the absolute risk of myopathy is low in patients taking simvastatin. A myopathy risk score showed no association with other muscle symptoms in these patients.
AHA 2020 Prof. Francis presents and interprets the findings of the SAMSON trial, in which symptom burden during statin, placebo and tablet-free periods was examined in patients who previously discontinued statins.
AHA 2020 The SAMSON trial showed that 90% of symptom burden in patients who previously discontinued statins is elicited by placebo tablets.
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.
Identifying and treating classic CV risk factors is important in patients with diabetes to reduce their CV risk. Prof. Hobbs discusses the classic CV risk factors one by one.
Attainment of 2016 guideline-recommended risk-based LDL-c goal was 54% and for 2019 risk-based LDL-c goal this was 33% in patients on lipid-lowering therapy in primary and secondary settings.
ESC 2020 Evolocumab, in addition to standard lipid-lowering therapies, resulted in a placebo-corrected difference of 38.3% for LDL-c after 24 weeks in pediatric HeFH patients.
Treatment with the PCSK9 inhibitor evolocumab reduced a composite of CV events compared to placebo in ASCVD patients with and without metabolic syndrome in a similar degree.
